The Prevalence of Low-Value Prostate Cancer Screening in Primary Care Clinics: A Study Using the National Ambulatory Medical Care Survey

References

1. 1.↵
   American Cancer Society [Internet]. Key statistics for prostate cancer; 2021. Available from: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html. Accessed December 21, 2021.
2. 2.↵
   1. Mariotto AB,
   2. Yabroff KR,
   3. Shao Y,
   4. Feuer EJ,
   5. Brown ML

   . Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011;103:117–28.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Siegel DA,
   2. O'Neil ME,
   3. Richards TB,
   4. Dowling NF,
   5. Weir HK

   . Prostate cancer incidence and survival, by state and race/ethnicity—United States, 2001–2017. Morb Mortal Wkly Rep 2020;69:1473–80.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Fenton JJ,
   2. Weyrich MS,
   3. Durbin S,
   4. et al

   . Prostate-specific antigen-based screening for prostate cancer: a systematic evidence review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK518892/.
5. 5.↵
   United States Preventive Services Task Force [Internet]. Final recommendation statement, prostate cancer; 2018. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening. Accessed November 15, 2021.
6. 6.↵
   1. Carter HB,
   2. Albertsen PC,
   3. Barry MJ,
   4. et al

   . Early detection of prostate cancer: AUA guideline. J Urol 2013;190:419–26.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   Center for Value-Based Insurance Design [Internet]. Reducing the utilization of low-value care; 2022. Available from: https://vbidcenter.org/initiatives/low-value-care/. Accessed May 6, 2022.
8. 8.↵
   1. Schuttner L,
   2. Haraldsson B,
   3. Maynard C,
   4. et al

   . Factors associated with low-value cancer screenings in the Veterans Health Administration. JAMA Netw Open 2021;4:e2130581.

   OpenUrl
9. 9.↵
   1. Park S,
   2. Jung J,
   3. Burke RE,
   4. Larson EB

   . Trends in use of low-value care in traditional fee-for-service Medicare and Medicare Advantage. JAMA Netw Open 2021;4:e211762.

   OpenUrl
10. 10.↵
    1. Oswald N,
    2. Lin T,
    3. Haaland B,
    4. et al

    . Factors associated with appropriate and low-value PSA testing. Cancer Epidemiol 2020;66:101724.

    OpenUrl
11. 11.↵
    United States Preventive Services Task Force [Internet]. Final recommendation statement: prostate cancer: screening; 1996. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening-1996. Accessed December 21, 2021.
12. 12.↵
    United States Preventive Services Task Force [Internet]. Final recommendation statement: prostate cancer: screening; 2008. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening-2008. Accessed December 21, 2021.
13. 13.↵
    Centers for Disease Control and Prevention [Internet]. About the Ambulatory Health Care Surveys; 2021. Available from: https://www.cdc.gov/nchs/ahcd/about_ahcd.htm. Accessed December 21, 2021.
14. 14.↵
    Centers for Disease Control and Prevention [Internet]. Ambulatory Health Care data: survey methods and analytic guidelines; 2021. Available from: https://www.cdc.gov/nchs/ahcd/survey_methods.htm. Accessed December 21, 2021.
15. 15.↵
    Centers for Disease Control and Prevention [Internet]. National Ambulatory Medical Care Survey dataset documentation; 2021. Available from: https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NAMCS/. Accessed December 21, 2021.
16. 16.↵
    1. Akinbami LJ,
    2. Santo L,
    3. Williams S,
    4. Rechtsteiner EA,
    5. Strashny A

    . Characteristics of asthma visits to physician offices in the United States: 2012–2015 National Ambulatory Medical Care Survey. Natl Health Stat Report 2019;1–20.
17. 17.↵
    1. Shahangian S,
    2. Fan L,
    3. Sharma KP,
    4. Siegel DA

    . Use of the prostate-specific antigen (PSA) test in the United States for men aged ≥65, 1999–2015: implications for practice interventions. Cancer Rep 2021;4:e1352.

    OpenUrl
18. 18.↵
    1. Babitsch B,
    2. Gohl D,
    3. von Lergerke T

    . Re-revisiting Andersen’s Behavioral Model of Health Services Use: a systematic review of studies from 1998–2011. Psychosoc Med 2012;9:Doc11.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Ioannidis JPA

    . The proposal to lower P value thresholds to.005. JAMA 2018;319:1429–30.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Mafi JN,
    2. Reid RO,
    3. Baseman LH,
    4. et al

    . Trends in low-value health service use and spending in the US Medicare Fee-for-Service program, 2014–2018. JAMA Netw Open 2021;4:e2037328.

    OpenUrl
21. 21.↵
    1. Shoag J,
    2. Halpern JA,
    3. Lee DJ,
    4. et al

    . Decline in prostate cancer screening by primary care physicians: an analysis of trends in the use of digital rectal examination and prostate specific antigen testing. J Urol 2016;196:1047–52.

    OpenUrl
22. 22.↵
    1. Desai MM,
    2. Cacciamani GE,
    3. Gill K,
    4. et al

    . Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open 2022;5:e222246.

    OpenUrl
23. 23.↵
    1. Thibault GE

    . Diagnostic strategy—the shotgun versus the arrow. N Engl J Med 1995;332:321–5.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Bouck Z,
    2. Calzavara AJ,
    3. Ivers NM,
    4. et al

    . Association of low-value testing with subsequent health care use and clinical outcomes among low-risk primary care outpatients undergoing an annual health examination. JAMA Intern Med 2020;180:973–83.

    OpenUrl
25. 25.↵
    1. Vernooij RWM,
    2. Lytvyn L,
    3. Pardo-Hernandez H,
    4. et al

    . Values and preferences of men for undergoing prostate-specific antigen screening for prostate cancer: a systematic review. BMJ Open 2018;8:e025470.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Ries NM,
    2. Jansen J

    . Physicians’ views and experiences of defensive medicine: an international review of empirical research. Health Policy 2021;125:634–42.

    OpenUrlPubMed
27. 27.↵
    1. Merenstein D

    . Winners and losers. JAMA 2004;291:15–6.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Jemal A,
    2. Fedewa SA,
    3. Ma J,
    4. et al

    . Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 2015;314:2054–61.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Leapman MS,
    2. Wang R,
    3. Park H,
    4. et al

    . Changes in prostate-specific antigen testing relative to the revised US Preventive Services Task Force recommendation on prostate cancer screening. JAMA Oncol 2022;8:41–7.

    OpenUrl
30. 30.↵
    1. Fedewa SA,
    2. Ward EM,
    3. Brawley O,
    4. et al

    . Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States. JAMA Intern Med 2017;177:1040–2.

    OpenUrl
31. 31.↵
    Centers for Disease Control and Prevention [Internet]. Ambulatory Care Monthly News; 2021. Available from: https://www.cdc.gov/nchs/ahcd/ambulatory_news.htm. Accessed May 17, 2022.
32. 32.↵
    1. Ganguli I,
    2. Shi Z,
    3. Orav EJ,
    4. et al

    . Declining use of primary care among commercially insured adults in the United States, 2008–2016. Ann Intern Med 2020;172:240–7.

    OpenUrlCrossRefPubMed